CancerDR: Cancer drug resistance database

117Citations
Citations of this article
229Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cancer therapies are limited by the development of drug resistance, and mutations in drug targets is one of the main reasons for developing acquired resistance. The adequate knowledge of these mutations in drug targets would help to design effective personalized therapies. Keeping this in mind, we have developed a database CancerDR, which provides information of 148 anti-cancer drugs, and their pharmacological profiling across 952 cancer cell lines. CancerDR provides comprehensive information about each drug target that includes; (i) sequence of natural variants, (ii) mutations, (iii) tertiary structure, and (iv) alignment profile of mutants/variants. A number of web-based tools have been integrated in CancerDR. This database will be very useful for identification of genetic alterations in genes encoding drug targets, and in turn the residues responsible for drug resistance. CancerDR allows user to identify promiscuous drug molecules that can kill wide range of cancer cells. CancerDR is freely accessible at http://crdd.osdd.net/raghava/cancerdr/.

Cite

CITATION STYLE

APA

Kumar, R., Chaudhary, K., Gupta, S., Singh, H., Kumar, S., Gautam, A., … Raghava, G. P. S. (2013). CancerDR: Cancer drug resistance database. Scientific Reports, 3. https://doi.org/10.1038/srep01445

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free